UAE Heart Failure Treatment Drugs Market to Surpass US$ 97.5 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE–(BUSINESS WIRE)–#HeartFailureTreatment–According to Coherent Market Insights, the UAE Heart Failure Treatment Drugs Market is estimated to be valued at US$ 62.8 million in 2020 and is expected to exhibit a CAGR of 6.5% during the forecast period (2020-2027).

Key Trends and Analysis of the UAE Heart Failure Treatment Drugs Market:

Increasing research and development of novel products is expected to drive the segment growth during the forecast period. For instance, currently (as of July 30th 2020), AstraZeneca Plc. has 166 clinical trial projects in its pipeline, among which 33 clinical trial projects are for cardiovascular, renal & metabolism business segment.

Moreover, product approvals from regulatory authorities is expected to drive the UAE heart failure treatment drugs market. For instance, in May 2020, the U.S. Food and Drug Administration granted the Fast Track designation for omecamtiv mecarbil, developed by Amgen and Cytokinetics, Inc. Omecamtiv mecarbil is a novel selective cardiac myosin activator, also known as a cardiac myotrope, being developed for the potential treatment of chronic heart failure with reduced ejection fraction (HFrEF).

Furthermore, in May 2020, AstraZeneca Plc. received the U.S. Food and Drug Administration approval for its Farxiga (dapagliflozin), a sodium glucose co-transporter 2 (SGLT2) inhibitor to reduce the risk of cardiovascular (CV) death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) and reduced ejection fraction (HFrEF) with and without type-2 diabetes (T2D).

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4172

Key Market Takeaways:

The UAE heart failure treatment drugs market is expected to exhibit a CAGR of 6.5% during the forecast period owing to approval of new products by regulatory authorities. For instance, in July 2015, Novartis International AG received the U.S. Food and Drug Administration approval for its cardiovascular drug, Entresto, for the treatment of patients with chronic heart failure.

The increasing incidence of chronic cardiovascular diseases is driving demand for drugs for treatment of cardiovascular diseases. Moreover, the rising healthcare expenditure in GCC countries driven by government funding for healthcare centers is expected to favor the segment growth. As per data of United States (U.S.) export, in 2018, the UAE’s healthcare expenditure reached US$ 13.7 billion and the spending is expected to reach US$ 18.3 billion by 2023.

Competitive Landscape:

Key players operating in the UAE Heart Failure Treatment Drugs Market are Novartis International AG, AstraZeneca Plc., Amgen, Inc., Pfizer, Inc., Mylan N.V., Merck & Co., Inc., Bristol-Myers Squibb, GlaxoSmithKline Plc., and Teva Pharmaceutical Industries Ltd.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4172

Market Segmentation:

  • UAE Heart Failure Treatment Drugs Market, By Drug Class:

    • ACE Inhibitors
    • Angiotensin 2 Receptor Blockers
    • Beta Blockers
    • Diuretics
    • Aldosterone Antagonists
    • Inotropes
    • Others
  • UAE Heart Failure Treatment Drugs Market, By Distribution Channel:

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Related Market Intelligence Report:

Asia Gout Disease Treatment Market, By Drug Class (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, and Urate-lowering Agents), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Country (China, India, Japan, South Korea, Thailand, Indonesia, Singapore, Vietnam, and Rest of Asian Countries) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more: https://www.coherentmarketinsights.com/market-insight/asia-gout-disease-treatment-market-4141

Hemorrhagic Shock Treatment Market, by Drug (NVX-408, YW-356, LB-1148, Neutrolide, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channels), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more: https://www.coherentmarketinsights.com/market-insight/hemorrhagic-shock-treatment-market-4097

Visceral Pain Treatment Market, by Drug Type (Pain modifiers (Tricyclic Anticonvulsant and Tricyclic Antidepressants), Analgesics (Narcotics and NSAID), and Others), by Indication (Chronic prostatitis, Interstitial cystitis, Crohn’s Disease, and Irritable Bowel Syndrome), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Channels), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more: https://www.coherentmarketinsights.com/market-insight/visceral-pain-treatment-market-4095

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Contacts

Mr. Shah

Senior Client Partner – Business Development

Coherent Market Insights

Phone:
US: +1-206-701-6702

UK: +44-020-8133-4027

Japan: +81-050-5539-1737

India: +91-848-285-0837

Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter